Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on PolyPid (PYPD) to $9 from $12 primarily due to a higher forecasted share count in Q1 2026, while keeping a Buy rating on the shares. The firm notes PolyPid has executed a new financing agreement that will infuse about $27M worth of cash into its coffers, allowing the company to schedule a pre-NDA meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial
- PolyPid price target lowered to $14 from $16 at Citizens JMP
- PolyPid price target raised to $13 from $11 at H.C. Wainwright
- PolyPid’s D-PLEX100: Compelling Phase 3 Results and Strong Commercial Prospects Justify Buy Rating
- PolyPid’s D-PLEX100 Achieves Positive Phase 3 Results in SHIELD II Trial